3e2f2be1-9d8d-4412-92eb-9f3d5c3ea3ef
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 86
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- PANCREAS_BETA_CELLS+0.350
- ANGIOGENESIS+0.340
- E2F_TARGETS+0.280
- INTERFERON_ALPHA_RESPONSE+0.280
- ADIPOGENESIS+0.260
- IL6_JAK_STAT3_SIGNALING+0.260
- PEROXISOME+0.230
- ANDROGEN_RESPONSE+0.220
Top 10 suppressed
- HYPOXIA-0.260
- TNFA_SIGNALING_VIA_NFKB-0.260
- APICAL_SURFACE-0.180
- WNT_BETA_CATENIN_SIGNALING-0.160
- MITOTIC_SPINDLE-0.140
- P53_PATHWAY-0.130
- ESTROGEN_RESPONSE_EARLY-0.120
- HEME_METABOLISM-0.110
- KRAS_SIGNALING_DN-0.100
- HEDGEHOG_SIGNALING-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0e1c98de-b4e2-4f42-beca-9948f867a46b | — | — | 0.773 |
| 2 | TCGA-E7-A7DV-01A-11R-A33J-07 | — | — | 0.731 |
| 3 | 65fc5187-8157-4af4-b4a5-6f6c2eca70ca | — | — | 0.729 |
| 4 | AUR-AFUG-TTM1-A-1-1-R-A743-41 | — | C | 0.719 |
| 5 | SJEPD030367_D2.RNA-Seq | EPN | Supratentorial EPN | 0.716 |
| 6 | cb6e4e0c-6f89-4ea5-a89d-1b0da8cf7fac | — | — | 0.716 |
| 7 | SRR8942962 | — | — | 0.715 |
| 8 | TCGA-46-3769-01A-01R-0980-07 | — | cohortA1 | 0.712 |
| 9 | BS_2EN3X6HB | high-grade glioma | — | 0.704 |
| 10 | SRR1313168 | — | E | 0.701 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |